Figure 1
From: OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma
Sorafenib induces apoptosis in hepatocellular carcinoma (HCC) cells. (a) Huh7 and LH86 cells were treated with sorafenib as indicated. The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay was performed to detect cell viability (*P<0.05, #P<0.05). (b) Cells were treated with sorafenib as indicated. Nuclear condensation was assessed by Hoechst staining to show apoptotic nuclei as described in ‘Materials and Methods’. (c) Cells were treated with sorafenib and nuclear condensation was assessed by 33258 staining. The apoptosis ratio was analyzed by counting cells with apoptotic nuclei under a fluorescent microscope (representative apoptotic cells were marked with white arrows, *P<0.05). (d) Cells were treated with sorafenib and DNA ladder assay was carried out to show DNA fragmentation (M: 1 kb plus DNA marker). (e) HCC cells were treated with sorafenib (20 μM) for different times (top panel) or were treated with various concentrations of sorafenib for 24 h (bottom panel). Cell lysates were prepared and subjected to western blotting to examine cleaved caspase 9 and caspase 3 protein levels with specific antibodies. β-Actin was used as an equal protein loading control.
